Welcome to our dedicated page for Gt Biopharma news (Ticker: GTBP), a resource for investors and traders seeking the latest updates and insights on Gt Biopharma stock.
GT Biopharma Inc. (NASDAQ: GTBP) is a clinical-stage immuno-oncology company developing cancer therapeutics based on its proprietary TriKE natural killer (NK) cell engager platform. The GTBP news feed on Stock Titan aggregates company press releases, clinical updates, financial disclosures, and other public announcements so readers can follow how its NK cell–based programs progress over time.
News about GT Biopharma frequently centers on its lead clinical candidate GTB-3650, a second-generation TriKE being evaluated in a Phase 1 dose-escalation trial for relapsed or refractory CD33-expressing hematologic malignancies, including acute myeloid leukemia and high-risk myelodysplastic syndrome. Regular updates describe enrollment status across multiple cohorts, results of formal safety reviews, early observations on immune activation and NK cell expansion, and plans for subsequent dose levels within the study protocol.
Another recurring theme in GTBP news is the advancement of GTB-5550, a camelid nanobody-based TriKE targeting B7-H3–expressing solid tumors. Company announcements cover key regulatory milestones such as submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration and outline the design of a planned Phase 1 basket trial using subcutaneous dosing across several metastatic solid tumor cohorts.
Investors and observers will also find financial result releases, which summarize cash position, research and development spending related to GTB-3650 and GTB-5550, and general operating expenses, along with 8-K-linked updates on Nasdaq listing matters and capital structure changes. Conference participation notices and board or governance updates provide additional context on how GT Biopharma presents its NK cell engager strategy to the investment community.
By reviewing GTBP news on this page, readers can track clinical milestones, regulatory interactions, financing developments, and corporate actions that shape the company’s progress in NK cell–based immuno-oncology.
GT Biopharma (NASDAQ: GTBP) announced its participation in three key medical conferences showcasing its innovative TriKE® technology. The upcoming presentations include:
- ESMO Targeted Anticancer Therapies Congress: March 7-8, 2022, focusing on NK cell immunotherapy.
- 48th Annual EBMT: March 19-23, 2022, discussing TriKE against multiple myeloma.
- AACR Annual Meeting: April 8-13, 2022, highlighting TriKE’s role in treating head and neck cancers.
These conferences may bolster investor interest and enhance the company's visibility in the oncology sector.
GT Biopharma (NASDAQ: GTBP) announced the immediate appointment of Manu Ohri as its new Chief Financial Officer (CFO). With over 25 years of management and finance experience, Ohri's previous roles include CFO for various public companies and management consultant in the biotech sector. His expertise is expected to strengthen the company's financial management and enhance communication with capital markets. GT Biopharma recently reported positive data from first-in-human trials of its TriKE® platform, marking a significant milestone in its clinical development efforts.
GT Biopharma (NASDAQ: GTBP), a clinical stage immuno-oncology company, announced that Dr. Greg Berk, President of R&D and Interim CEO, will participate in a Fireside Chat at the B. Riley Securities' Virtual Oncology Conference. The event is scheduled for January 27, 2022, at 9:30 A.M. EST. This conference will showcase innovations in immuno-oncology, particularly focusing on GT Biopharma's proprietary TriKE® NK cell engager platform, which aims to enhance the cancer-fighting abilities of natural killer cells. Further details and webcast information are available.
GT Biopharma, Inc. (NASDAQ: GTBP) has announced the approval of equity compensation awards to key employees as inducements to join the company, as per Nasdaq Listing Rule 5635(c)(4). The awards include options for Gavin Choy (227,500 shares at $3.05 each), Leslie Bransfield (75,000 shares at $3.05), and a stock award for Kathy Quandt (50,000 shares). The options have a 10-year term, with specific vesting schedules. GT Biopharma focuses on developing immuno-oncology therapies utilizing its TriKE® platform, licensed from the University of Minnesota.
GT Biopharma, Inc. (NASDAQ: GTBP) announced the availability of its mini-poster presentation at the ESMO Immuno-Oncology Congress 2021 in Geneva, Switzerland, from December 8-11, 2021. The presentation focuses on GTB-5550, a dual camelid nanobody that targets the B7-H3 molecule, showing effective NK cell activation against various tumors, including enzalutamide-resistant prostate cancer. The company is advancing its TriKE® technology platform, and GMP production of GTB-5550 has begun, indicating significant progress in its clinical pipeline.
GT Biopharma (NASDAQ: GTBP) announced the acceptance of an abstract for presentation at the ESMO Immuno-Oncology Congress 2021, scheduled for December 8-11, 2021, in Geneva, Switzerland. The e-Poster titled 'Novel B7-H3 targeting dual nanobody NK cell engagers display robust activity against a broad spectrum of solid and hematologic malignancies' emphasizes the potential of their TriKE® technology. Full abstracts will be published on December 2, 2021, at 12:00 pm CET, and the company will share its poster on its website during the conference.
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company, will host a Management Update Conference Call on November 30, 2021, at 4:30 PM ET. The call features Michael Breen, Executive Chairman, and Dr. Greg Berk, Chief Medical Officer. Participants can join via a live webcast or by phone at toll-free 1-877-407-9039 (international: 1-201-689-8470). An archived replay will be available on the company’s website post-event. The conference will discuss the company’s innovative TriKE platform, focused on enhancing NK cell cancer therapies.
GT Biopharma (NASDAQ: GTBP) reported its third quarter 2021 results, highlighting significant advancements in its TriKE platform. Key achievements include securing new intellectual property protecting the platform through 2036 and demonstrating proof of concept safety data from its Phase 1 clinical trial. The Company reported cash and cash equivalents of $35.8 million as of September 30, 2021, up from $7 million at the end of 2020. However, R&D expenses surged to $1 million from $84,000 in Q3 2020, reflecting increased clinical trial activity. The net loss was $5.5 million, compared to a $2.9 million loss in the prior year.
GT Biopharma, Inc. (NASDAQ: GTBP) announced a major restructuring of its executive management team on November 8, 2021. Chairman and CEO Anthony Cataldo and CFO Michael Handelman will depart to pursue other interests. The Board appointed Dr. Gregory Berk as interim CEO and Dr. Gavin Choy as acting CFO. Michael Breen becomes Executive Chairman and oversees the transition. The company is seeking permanent replacements for the CEO and CFO roles. GT Biopharma focuses on developing immunotherapies based on its proprietary TriKE® platform aimed at transforming cancer treatment.
GT Biopharma (NASDAQ: GTBP) announced that Dr. Jeffrey Miller presented at the ESMO Congress 2021, showcasing the efficacy of camelid TriKEs in targeting solid tumors. The Company plans to advance these TriKEs into clinical trials in 2022. They also provided updates on the ongoing Phase 1 clinical trial of GTB-3550, which has shown safety and early anti-leukemic activity in patients with AML and MDS. The treatment was well tolerated, with one patient experiencing a mild cytokine release syndrome event.